BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 19846394)

  • 1. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
    Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
    Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
    Sims K; Politei J; Banikazemi M; Lee P
    Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study.
    Tsakiris DJ; Stel VS; Finne P; Fraser E; Heaf J; de Meester J; Schmaldienst S; Dekker F; Verrina E; Jager KJ
    Nephrol Dial Transplant; 2010 Apr; 25(4):1200-6. PubMed ID: 20037169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden.
    Evans M; Fryzek JP; Elinder CG; Cohen SS; McLaughlin JK; Nyrén O; Fored CM
    Am J Kidney Dis; 2005 Nov; 46(5):863-70. PubMed ID: 16253726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictors of early death during dialysis].
    Caravaca F; Arrobas M; Pizarro JL; Cancho B; Cubero JJ; Espárrago JF; García MC; Sánchez-Casado E
    Nefrologia; 2001; 21(3):274-82. PubMed ID: 11471308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional and social inequalities in chronic renal replacement therapy in Denmark.
    Hommel K; Rasmussen S; Kamper AL; Madsen M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2624-32. PubMed ID: 20207710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006.
    Kramer A; Stel V; Zoccali C; Heaf J; Ansell D; Grönhagen-Riska C; Leivestad T; Simpson K; Pálsson R; Postorino M; Jager K;
    Nephrol Dial Transplant; 2009 Dec; 24(12):3557-66. PubMed ID: 19820003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events in patients with fabry disease natural history data from the fabry registry.
    Patel MR; Cecchi F; Cizmarik M; Kantola I; Linhart A; Nicholls K; Strotmann J; Tallaj J; Tran TC; West ML; Beitner-Johnson D; Abiose A
    J Am Coll Cardiol; 2011 Mar; 57(9):1093-9. PubMed ID: 21349401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
    Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
    G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal replacement therapy for diabetic end-stage renal disease. Experience of a Tunisian hospital centre.
    Abderrahim E; Zouaghi K; Hedri H; Ben Abdallah T; Ben Hamida F; Kaaroud H; Goucha R; Ben Abdallah N; Khiari K; El Younsi F; Ben Moussa F; Kheder A; Ben Maïz H
    Diabetes Metab; 2001 Nov; 27(5 Pt 1):584-90. PubMed ID: 11694858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of a pre-dialysis education programme (PDEP) on the mode of renal replacement therapy.
    Goovaerts T; Jadoul M; Goffin E
    Nephrol Dial Transplant; 2005 Sep; 20(9):1842-7. PubMed ID: 15919693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
    Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
    Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.
    Hopkin RJ; Bissler J; Banikazemi M; Clarke L; Eng CM; Germain DP; Lemay R; Tylki-Szymanska A; Wilcox WR
    Pediatr Res; 2008 Nov; 64(5):550-5. PubMed ID: 18596579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.